MLchartDataset catalogue

Girentuximab

Term · Oncology and biomedicine · MLC-T-ONC-013948

A chimeric monoclonal antibody directed against G250, a cell surface antigen found in the majority of renal cell carcinomas. Following binding, girentuximab may be internalized by G250 antigen-expressing renal carcinoma cells; mAb G250 may be useful as a carrier for radioisotopes and other antineoplastic therapeutic agents.

Table 1. Record
IdentifierMLC-T-ONC-013948
FieldOncology and biomedicine
AbbreviationMOAB G250
SynonymsWX-G250; monoclonal antibody G-250; chimeric monoclonal antibody cG250
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-013948",
  "term": "Girentuximab",
  "field": "Oncology and biomedicine",
  "definition": "A chimeric monoclonal antibody directed against G250, a cell surface antigen found in the majority of renal cell carcinomas. Following binding, girentuximab may be internalized by G250 antigen-expressing renal carcinoma cells; mAb G250 may be useful as a carrier for radioisotopes and other antineoplastic therapeutic agents.",
  "abbreviation": "MOAB G250",
  "synonyms": [
    "WX-G250",
    "monoclonal antibody G-250",
    "chimeric monoclonal antibody cG250"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/girentuximab/"
}

Record 7,989 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.